1. Introduction {#sec1-cancers-11-01838}
===============

Neurofibromatosis type 1 (NF1) is a multi-system, tumour-prone disorder that is diagnosed on the basis of established clinical criteria \[[@B1-cancers-11-01838],[@B2-cancers-11-01838]\]. It is one of the most frequently inherited genetic conditions (its worldwide prevalence is about 1/3000 people), and it is characterised by complete and age-related penetrance and highly variable expression \[[@B3-cancers-11-01838],[@B4-cancers-11-01838],[@B5-cancers-11-01838]\]. It is caused by constitutional dominant loss-of-function intragenic mutations or the deletion of the *NF1* gene (OMIM 613113) located on the long arm of human chromosome 17. With its 61 exons, four of which are alternatively spliced, *NF1* is one of the largest genes and has one of the highest mutation rates in the human genome \[[@B6-cancers-11-01838],[@B7-cancers-11-01838]\].

The gene encodes for neurofibromin, a ubiquitous 2818 amino acid protein with various domains, the most widely known of which is the GTPase-activating protein (GAP)-related domain (GRD), which exerts tumour suppressing activity by down-regulating the Ras signalling pathway \[[@B8-cancers-11-01838]\].

Although less well-characterised, the other *NF1* domains that have been described are the cysteine/serine-rich domain (CSRD), the tubulin-binding domain (TBD), the Sec14 homology-like (Sec14) domain, the pleckstrin homology-like (PH) domain, the HEAT-like repeat regions (HLR), the C-terminal domain (CTD), the nuclear localisation signal region (NLS), and the syndecan-2 binding region (SBR) \[[@B8-cancers-11-01838]\].

The enormous number of reported pathogenic *NF1* variations consist of intragenic *NF1* mutations, which are found in about 90% of NF1 patients, and large 17q11.2 deletions encompassing the entire *NF1* gene and a number of flanking genes (the *NF1* microdeletion), which are found in 5%--10% \[[@B9-cancers-11-01838]\]. Point mutations are observed in all exons and are mostly nulling or protein-truncating mutations, while a minority (9.4%--15%) are missense mutations \[[@B10-cancers-11-01838],[@B11-cancers-11-01838],[@B12-cancers-11-01838]\].

The reported detection rates range from 60% to 97% depending on the technique used and the source of the tissues. Advances in genetic investigation techniques have allowed a molecular diagnosis to be made in the majority of cases using multiple gene DNA and RNA screening approaches: Sanger sequencing, next-generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridisation CGH \[[@B9-cancers-11-01838],[@B10-cancers-11-01838],[@B11-cancers-11-01838]\].

NF1 patients may present a wide range of multi-system complications and are prone to developing benign and malignant tumours of the central and peripheral nervous systems, as well as systemic malignancies \[[@B13-cancers-11-01838]\]. They consequently need periodic monitoring in order to minimise the risk of serious medical complications \[[@B14-cancers-11-01838]\]. About 15%--20% of patients develop low-grade glial tumours, 80% of which involve the optic pathway \[[@B15-cancers-11-01838]\].

Optic pathway glioma (OPG), a predominantly World Health Organisation (WHO) grade I astrocytoma, is one of the diagnostic criteria for NF1 and the most frequently identified brain tumour in NF1 children \[[@B1-cancers-11-01838],[@B15-cancers-11-01838]\]. In NF1 children aged \<7 years, it can arise anywhere along the optic pathway from the retro-orbital optic nerve to the post-chiasmatic optic traits and radiations. It is usually infiltrative, has a low proliferative index, and there is no defined cystic component. Although its course is more indolent and favourable than sporadic optic pathway glioma, and it occasionally regresses spontaneously \[[@B16-cancers-11-01838],[@B17-cancers-11-01838],[@B18-cancers-11-01838],[@B19-cancers-11-01838]\], up to half of the patients develop clinical symptoms, such as reduced visual acuity, pale papillae of the optic nerve, strabismus, proptosis, and endocrinological abnormalities, particularly precocious puberty \[[@B20-cancers-11-01838]\].

OPG in NF1 patients still raises many questions regarding screening and surveillance \[[@B21-cancers-11-01838]\]. Contrast-enhanced brain magnetic resonance imaging (MRI) is the standard imaging technique used to identify and monitor OPG \[[@B2-cancers-11-01838],[@B22-cancers-11-01838]\], but it is very costly and its use for screening purposes is controversial. The Optic Pathway Task Force has recommended against it because radiological and clinical findings do not match sufficiently, asymptomatic OPGs do not require treatment, and anesthesia is a risk for small children. However, an early OPG diagnosis in young children may improve the outcome \[[@B15-cancers-11-01838],[@B21-cancers-11-01838],[@B23-cancers-11-01838]\].

There is a general consensus regarding the usefulness of an ophthalmological evaluation at least once a year up to 10 years of age, but visual acuity measurements are not always reliable in small children \[[@B15-cancers-11-01838],[@B24-cancers-11-01838]\].

In this context, the challenge is to predict which children may develop OPG and which OPG may reduce visual acuity and/or lead to symptoms and signs.

Tumour localisation in the optic chiasm and/or posterior optic tracts, an early age at the time of tumour onset, and being a female all seem to lead to a worse prognosis, but the evidence is not sufficient to propose different surveillance strategies \[[@B15-cancers-11-01838],[@B24-cancers-11-01838]\].

Over the last few years, many authors have focused on genotype--phenotype correlations in patients with NF1, and the findings of some studies suggest that the genotype may be the main determinant of the development of OPG in NF1 children.

Patients with *NF1* gene mutations in the 5' tertile (exon 1--21) and the CSRD (residues 543--909) seem to be at a higher risk of developing OPG \[[@B25-cancers-11-01838],[@B26-cancers-11-01838],[@B27-cancers-11-01838],[@B28-cancers-11-01838],[@B29-cancers-11-01838]\], whereas patients with mutations in the HLR (residues 1825--2428) located in the 3' tertile (exon 39--57) seem to be at lower risk \[[@B28-cancers-11-01838]\]. In addition, OPG seems to be more strongly associated with patients with 5'-end truncating or nonsense mutations \[[@B27-cancers-11-01838]\].

The aim of this collaborative retrospective study was to confirm these correlations by gathering information concerning a large independent cohort of unrelated NF1 patients with defined constitutional *NF1* mutations who have undergone brain MRI.

Identifying an association between the risk of developing OPG and specific *NF1* mutations is an attractive prospect as it would be very helpful in genetic counselling, as well as in guiding screening and surveillance during childhood. In the long term, it may also be useful in further clarifying the pathogenesis of OPGs and developing targeted treatments.

2. Materials and Methods {#sec2-cancers-11-01838}
========================

2.1. Study Subjects {#sec2dot1-cancers-11-01838}
-------------------

The study involved patients from four regional NF1 referral centres: Fondazione IRCCS Istituto Neurologico Carlo Besta and Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico in Milan, Istituto Giannina Gaslini in Genoa, and Spedali Civili in Brescia.

The study inclusion criteria were as follows:-a clinical diagnosis of NF1 based on the 1988 NIH diagnostic criteria \[[@B1-cancers-11-01838]\];-a defined constitutional *NF1* mutation;-brain MRI scans available in the institutional picture archiving and communication system (PACS).

We excluded the following: -the youngest patients in familial cases in order to include patients with a more expressed phenotype and to avoid any confounding effects due to shared polymorphisms in possible modifying genes in family members;-patients in whom the entire *NF1* gene and flanking genes were deleted (microdeletion) because it is not possible to study the correlation between the localisation of the mutation and phenotype in such patients;-patients harbouring more than one variant of the *NF1* gene because the role of each variant needs to be tested separately;-patients with increased optic nerve tortuosity and nerve or sheath thickening without any clear signs of OPG because of the uncertain significance of these characteristics in terms of the subsequent development of OPG \[[@B30-cancers-11-01838]\]; and-patients aged \<10 years without an MRI detected OPG because they are still at risk of developing OPG.

The patients were selected using the clinical data in their electronic medical records. The patients or their parents signed an informed consent form before MRI and genetic testing were carried out, and gave their consent to the use of the anonymous results for retrospective research studies. The investigations were carried out in accordance with the principles laid down in the 2013 revision of the Declaration of Helsinki. This retrospective study is part of an NF1 research line approved by the Fondazione IRCCS Istituto Neurologico Carlo Besta Scientific Board and, in accordance with Italian regulations, does not require specific ethical approval because it only uses anonymous data collected during routine patient care.

The indications for brain MRI were neurological and/or visual signs and symptoms, baseline screening at the time of the first evaluation, and radiological surveillance of OPG or other brain lesions.

The diagnosis of OPG in patients with NF1 is currently based on the pathognomonic characteristics of brain MRI; an OPG biopsy is not usually used because of the high risk of vision loss \[[@B31-cancers-11-01838]\].

The MRI examinations were performed using a 1.5 T or 3 T machine, and concentrated on the chiasmatic and orbital regions (differences in MRI resolution do not interfere with the detection of OPG). Two senior neuroradiologists (L.C. and S.A.) with more than 20 years' experience reviewed the neuroimages and confirmed the diagnosis of OPG on the basis of the pathognomonic characteristics of the brain MRI scans. Although there is no universally accepted radiological definition of NF1-associated OPG, the standard is an MRI scan of the brain and orbits using thin slices through the optic nerves and chiasm, including T1-weighted sequences with and without gadolinium, and T2-weighted sequences. As contrast enhancement may be heterogeneous, T2-weighted sequences often define the tumour borders more accurately \[[@B31-cancers-11-01838],[@B32-cancers-11-01838]\]. OPGs may show enlargement of the optic nerve, chiasm, optic tracts, and optic radiations. Gliomas of the optic nerve usually have a tubular/fusiform appearance with an often downward kink, whereas chiasmal gliomas can appear as an enlargement of the chiasm or a suprasellar mass. The radiographical interpretation of OPGs can be complicated by T2-hyperintense lesions (which are frequently detected in the brain of NF1 children) overlapping the borders of the tumour. In addition, OPGs are extra-axial and intra-dural and remain within the nerve sheath, which means they may resemble cerebrospinal fluid in T2-weighted sequences (the "pseudo-CSF" sign) \[[@B24-cancers-11-01838],[@B31-cancers-11-01838],[@B32-cancers-11-01838]\]. Tortuous optic nerves and optic nerve or sheath enlargements are quite frequently observed in MRI scans of NF1 children, but their significance in terms of the subsequent development of OPG is debated \[[@B30-cancers-11-01838]\]. In order to avoid missing or over-diagnosing OPGs, any doubtful cases without clear signs of an OPG (i.e., nerve tortuosity, suspected nerve, or sheath thickening) were excluded.

The patients were divided into two groups: NF1 patients of any age with an MRI confirmed diagnosis of OPG were included in the NF1 OPG group, whereas NF1 patients aged ≥10 years without any optic pathway tumour, as confirmed by MRI, were included in the NF1 non-OPG group (patients who have not developed an OPG by the age of 10 years are extremely unlikely to do so in later life) \[[@B21-cancers-11-01838]\]. A total of 255 patients were selected and included in the study: 92 with OPG and 163 without. The MRI data and ages reported herein are those of the latest clinical evaluation by the referring physicians co-authoring this paper.

2.2. Literature Review {#sec2dot2-cancers-11-01838}
----------------------

We systematically reviewed the recent scientific literature with the aim of increasing the number of cases to a minimum of 307 patients, because Anastasaki et al. have calculated that this number is needed to detect an effect size of 0.16 with 80% power using a chi-squared test to detect differences in proportions with an alpha level of 0.05 \[[@B27-cancers-11-01838]\].

We looked for NF1 patients who had not been described in previous studies of genotype--phenotype correlations in relation to the development of OPG \[[@B27-cancers-11-01838],[@B28-cancers-11-01838],[@B29-cancers-11-01838]\]. The studies were identified by searching the Pubmed (2017--present) and Google scholar (2017--present) medical databases using the following terms: NF1, neurofibromatosis, and genotype--phenotype or genotype or phenotype.

We only selected patients fulfilling the inclusion and exclusion criteria described above. In particular, we excluded all reports without enough information to allow us to assign patients to the OPG or non-OPG group. In order to be included in the non-OPG group, the patients had to have undergone negative MRI after the age of 10 years. The OPG group only included patients with a reported neuroradiological diagnosis of OPG; we did not have access to the radiological images, but assumed that the reported data were correct. We also excluded known familial cases (we checked whether there was consanguineity in patients sharing the same mutation). The only patients with the same mutation were patient number 144 in the series described by Tsipi et al. \[[@B33-cancers-11-01838]\] and patient number 10 in the series described by Ulusal et al. \[[@B34-cancers-11-01838]\] and, as these patients belonged to different cohorts and their mutation is known to be frequent, there is little likelihood of consanguineity. The two patients harbouring the same *NF1* mutation and retrieved from the paper by Trevisson et al. belonged to unrelated families \[[@B35-cancers-11-01838]\].

The literature review allowed us to select 54 patients; there were more patients in the OPG group (40) than in the non-OPG group (14) \[[@B33-cancers-11-01838],[@B34-cancers-11-01838],[@B35-cancers-11-01838],[@B36-cancers-11-01838],[@B37-cancers-11-01838],[@B38-cancers-11-01838],[@B39-cancers-11-01838],[@B40-cancers-11-01838],[@B41-cancers-11-01838]\].

2.3. Molecular Testing and Analysis of NF1 Mutations {#sec2dot3-cancers-11-01838}
----------------------------------------------------

Blood samples from 238 of the 255 patients attending the study centres were originally sent to the laboratory of the Molecular Neuro-oncology Unit of Fondazione IRCCS Istituto Neurologico Carlo Besta for molecular *NF1* genetic testing in order to establish or confirm the diagnosis of NF1.

Constitutional intragenic *NF1* mutations were determined by means of standard techniques using gDNA and, more recently, cDNA; that is, Sanger sequencing and NGS to test for point mutations, and MLPA to test for intragenic deletion/duplication \[[@B11-cancers-11-01838],[@B38-cancers-11-01838]\].

Genomic DNA was obtained from blood EDTA samples, and RNA samples were collected in Tempus blood RNA tubes and reverse-transcribed into cDNA. NGS was carried out using the Ion Sequencing Kit v2.0. Sanger sequencing was used for the oldest samples, for the positive amplicons and the cDNA of negative amplicons obtained by means of NGS Ion Torrent sequencing. MLPA was carried out using *NF1* MLPA salsa P081 and P082. The variants were defined in accordance with the reference sequence NM_000267.3 and human reference genome hg19.

When in vitro studies were not available, the effect of the identified mutations on genes and proteins were predicted by querying various prediction sites, including Mutation Taster (<http://www.mutationtaster.org>), and databases such as the National Center for Biotechnology Information (NCBI) Single Nucleotide Polymorphism database (dbSNP) and the 1000 Genomes Project (TGP) database: disease variants came from dbSNP (ClinVar) and from the Human Genome Mutation Database (HGMD) PolyPhen-2 (<https://genetics.bwh.harvard.edu./pph2/>). The possible effects on mRNA (canonical and non-canonical splicing mutations) were evaluated using neural network Splice site Prediction (<http://www.fruitfly.org/seq_tools/splice.html>) \[[@B42-cancers-11-01838]\], the Human Splicing Finder (HSF; <http:www.umd.be/HSF/>) \[[@B43-cancers-11-01838]\], and the ESE Finder (<http://rulai.cshl.edu/cgibin/tools/ESE3/esefinder.cgi?process=home>) \[[@B44-cancers-11-01838]\].

The mutations were classified as nonsense (NS), frameshift (FS), missense (MS), inframe (ID), or splicing (SS) mutations; or large deletion (LD) consisting of at least an entire exon. Care was taken when interpreting the effects of the mutations on proteins as some putative MS mutations may also cause splicing abnormalities \[[@B10-cancers-11-01838]\]; the exonic variations with effects on splicing were included in the splicing group. The novel mutations identified in this study were deposited with the LOVD database (<http://www.LOVD.nl/NF1>), and are described in accordance with HGSV recommendations.

On the basis of the criteria described by Sharif \[[@B25-cancers-11-01838]\], the mutations were attributed to tertiles: the 5' tertile spanning exons 1--21, the middle tertile spanning exons 22--38, and the 3' tertile spanning exons 39--57. The mutations were also mapped to a specific domain as indicated by Xu \[[@B28-cancers-11-01838]\], with residues 543--909 belonging to the cysteine/serine-rich domain (CSRD), residues 1095--1197 to the tubulin-binding domain (TBD), residues 1198--1530 to the GTPase activating protein-related domain (GRD), residues 1560--1705 to the Sec14-like domain (Sec14), residues 1716--1816 to the pleckstrin homology-like domain (PH), residues 1825--2428 to the HEAT-like repeat regions (HLR), residues 2260--2817 to the C-terminal domain (CTD), residues 2534--2550 to the nuclear localisation signal region (NLS), and residues 2619--2719 to the syndecan-binding region (SBR) \[[@B45-cancers-11-01838],[@B46-cancers-11-01838],[@B47-cancers-11-01838]\]. The *NF1* tertiles and neurofibromin domains are schematically shown in [Figure 1](#cancers-11-01838-f001){ref-type="fig"}.

2.4. Statistical Analysis {#sec2dot4-cancers-11-01838}
-------------------------

The χ2 test and Fisher's exact probability test were used to compare the frequencies of the independent variables (the locations of mutations by tertile and domain, and the type of mutations) between the NF1 OPG and the NF1 non-OPG group. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated. Genotype--phenotype associations were studied using multiple logistic regression. Bonferroni's method was used to correct *p*-values for multiple testing. *p*-values of \<0.05 were considered statistically significant. The descriptive, frequency, and comparative statistical analyses were carried out using SPSS 22.0 software.

3. Results {#sec3-cancers-11-01838}
==========

A total of 309 NF1 patients were selected on the basis of the inclusion and exclusion criteria and included in the study; 255 were recruited from the authors' institutions (92 with OPG and 163 without OPG) and 54 were retrieved from the recent literature (40 with OPG and 14 without OPG) \[[@B33-cancers-11-01838],[@B34-cancers-11-01838],[@B35-cancers-11-01838],[@B36-cancers-11-01838],[@B37-cancers-11-01838],[@B38-cancers-11-01838],[@B39-cancers-11-01838],[@B40-cancers-11-01838],[@B41-cancers-11-01838]\]. One hundred and thirty-two patients were included in the NF1 OPG group (61 females, 57 males; the sex of 14 patients retrieved from the literature was not reported) and 177 in the NF1 non-OPG group (91 females, 76 males; 10 unknown). [Table 1](#cancers-11-01838-t001){ref-type="table"} shows their clinical details (age, sex, OPG diagnosis); the molecular details (DNA, RNA, protein change); and the classification of the variants by type, tertile, and domain.

3.1. Distribution of NF1 Mutations by Tertile and the Risk of Developing OPG {#sec3dot1-cancers-11-01838}
----------------------------------------------------------------------------

The total number of patients harbouring mutations located in the 5', middle, and 3' tertile was 144 (46.60%, CI = 41.12%--52.17%), 104 (33.66%, CI = 28.62%--39.10%), and 61 (19.74%, CI = 15.69%--24.54%), respectively. The distribution of mutations was 57 (43.2%) in the 5' tertile, 47 (35.6%) in the middle tertile, and 28 (21.2%) in the 3' tertile in the NF1 OPG group, and 87 (49.2%), 57 (32.2%), and 33 (18.6%), respectively, in the NF1 non-OPG group ([Figure 2](#cancers-11-01838-f002){ref-type="fig"} and [Figure 3](#cancers-11-01838-f003){ref-type="fig"}).

There were no statistically significant differences between the two groups; in particular, the patients with OPG were not more likely to harbour 5' tertile mutations than those without OPG (43.6 vs. 49.2, *p* = 0.29) ([Table 2](#cancers-11-01838-t002){ref-type="table"}).

3.2. Distribution of NF1 Mutations by Domain and the Risk of Developing OPG {#sec3dot2-cancers-11-01838}
---------------------------------------------------------------------------

The analysis was extended to all of the *NF1* domains in order to evaluate whether the risk of developing OPG was associated with mutations in the CSRD and HLR, as previously reported. There were no statistically significant differences between the OPG and the non-OPG group. In particular, there were 20 mutations (15.2%) in the CSRD in the OPG group, and 30 (16.9%) in the non-OPG group (*p* = 0.67); and 25 mutations (18.9%) in the HLR domain in the OPG group, and 29 (16.4%) in the non-OPG group (*p* = 0.55) ([Table 3](#cancers-11-01838-t003){ref-type="table"}).

3.3. Spectrum of Mutation Types and the Risk of Developing OPG {#sec3dot3-cancers-11-01838}
--------------------------------------------------------------

The number of patients with frameshift, nonsense, splicing, missense, and inframe mutations and large deletions was 101 (32.7%), 85 (27.5%), 76 (24.6%), 33 (10.7%), 6 (1.9%), and 8 (2.6%), respectively.

The proportion of nonsense mutations was higher in the OPG group than in the non-OPG group (OR 1.77; CI = 1.07--2.93). However, when the *p*-value was adjusted for multiple comparisons, the difference was not statistically significant (*p* = 0.15) ([Table 4](#cancers-11-01838-t004){ref-type="table"}).

4. Discussion {#sec4-cancers-11-01838}
=============

The phenotypic expression of NF1 varies widely from mild cutaneous manifestations to serious complications, and is largely unpredictable because of the lack of robust prognostic risk factors. This unpredictability is one of the most difficult aspects of disease management for both patients and clinicians as it makes the genetic counselling and screening and surveillance of NF1 patients extremely challenging \[[@B13-cancers-11-01838],[@B14-cancers-11-01838],[@B48-cancers-11-01838]\].

In this context, any suggestion of a possible genotype--phenotype correlation arouses considerable interest as it might aid clinical care by offering an opportunity to better inform patients about what to expect in the future, and allowing personalised screening and monitoring based on changes in the *NF1* gene.

NF1 genotype--phenotype correlation studies began to be developed after the identification of the *NF1* gene in 1990 \[[@B49-cancers-11-01838],[@B50-cancers-11-01838]\], but they were limited by the difficulty of detecting *NF1* mutations until the recent development and spread of new genetic diagnostic investigational techniques gave them renewed impulse \[[@B51-cancers-11-01838]\].

However, identifying specific genotype--phenotype correlations is still very challenging because of the variability of the clinical presentation of the disease, the age-dependence of most of its features, the wide range of *NF1* gene variants (often considered private variations), and the timing and number of second hits in specific cells \[[@B52-cancers-11-01838]\]. Furthermore, given the phenotypic variability even among patients with familial NF1 who share the same germline mutation, it has been suggested that there are likely to be other influences such as modifier genes, as well as epigenetic and environmental factors, although their contribution to determining the phenotype is still unknown and may vary depending on disease traits \[[@B25-cancers-11-01838]\].

Despite all of these limitations, at least four genotype--phenotype correlations in NF1 have recently emerged, and others are still being studied.

Firstly, patients with large deletions of the *NF1* gene region and flanking genes (*NF1* microdeletions) tend to present a more severe phenotype in terms of cognitive impairment and/or learning disabilities, facial dysmorphisms and cardiovascular malformations, and are at increased risk of malignant peripheral nerve sheath tumours (MPNSTs) \[[@B53-cancers-11-01838]\].

Secondly, two specific intragenic mutations (a 3-bp in-frame deletion *NF1* c.2970_2972 del p.Met992del, and missense mutations affecting p.Arg1809) have been associated with distinct, but partially concordant mild clinical phenotypes, with the first being characterised by the absence of cutaneous neurofibromas and other serious complications \[[@B51-cancers-11-01838],[@B54-cancers-11-01838]\], and the second by the absence of cutaneous or plexiform neurofibromas with Noonan--like features \[[@B55-cancers-11-01838],[@B56-cancers-11-01838]\].

Finally, it has recently been found that patients with missense mutations involving one of the codons 844--848 within the CSRD have a more severe phenotype and are at a higher risk of developing MPNSTs, OPGs, and malignant neoplasms \[[@B52-cancers-11-01838]\].

In addition to these four genotype--phenotype correlations, the findings of recent studies suggest that the type and the position of *NF1* mutations may be the main determinant of the risk of developing spinal neurofibromas (patients more likely to have MS or SS mutations) \[[@B57-cancers-11-01838]\], pulmonary stenosis (a significantly higher prevalence of non-truncating *NF1* mutations) \[[@B58-cancers-11-01838]\], breast cancers (a higher proportion of both nonsense and missense mutations) \[[@B12-cancers-11-01838]\], and OPGs.

In 2011, Sharif et al. were the first to find a trend toward the clustering of pathogenic changes in the 5′ tertile (exons 1--21) of the *NF1* gene in 29 NF1-OPG patients from the United Kingdom \[[@B25-cancers-11-01838]\], and the same trend was found in another cohort of 20 NF1-OPG patients with 12 different mutations described by Ars \[[@B59-cancers-11-01838]\]. In order to determine whether the risk of developing OPG was associated with mutation location, Sharif et al. combined their finding with those of Ars and a larger series of Castle et al. \[[@B60-cancers-11-01838]\] to give a total of 125 NF1 patients (predominantly from the United Kingdom), 36 of whom had OPGs. Statistical analysis showed a significant distribution of mutations in the 5' tertile of the *NF1* gene in NF1 patients with OPGs when compared with NF1 patients without OPGs.

The clustering of mutations in the 5' tertile of NF1 gene in patients with OPG was subsequently supported by Bolcekova et al., who observed a similar *NF1* mutation pattern in their series of 25 Slovakian NF1-OPG patients in comparison with 27 NF1 controls \[[@B26-cancers-11-01838]\]. They found that 71% of the mutations in OPG patients were located in the first tertile as against 29% in the non-OPG group. They believed that the CSRD, which spans exons 11--17 in the first tertile of the gene, may be as important a functional domain as the RAS-GAP domain, and may play an important role in the development of OPG.

These associations were not confirmed by a subsequent study by Hutter et al. \[[@B61-cancers-11-01838]\], who used stricter inclusion criteria to select 77 NF1 patients from Germany and Canada (thus reducing regional genetic differences), and found a point mutation in 37 OPG patients and 32 controls. They observed a greater proportion of mutations in the 5' region in both the OPG (17/37, 46%) and non-OPG patients (15/32, 47%). In order to avoid misinterpreting data from small cohorts, they combined their series with that of Bolcekova et al., thus increasing the cohort to 129 NF1 patients (66 OPG and 63 non-OPG), but found no significant correlation between mutations in the 5' tertile of *NF1* and the development of OPG.

In 2017, Anastasaki et al. analysed 37 NF1 patients at Washington University (14 with OPG and 13 without) in order to ascertain the relationship between the type and the location of the germline *NF1* mutation and the presence of OPG, and did not find any statistically significant correlation \[[@B27-cancers-11-01838]\]. However, power calculations revealed that a sample size of 307 patients is required to determine the predictive value of the position or type of *NF1* gene mutations, and so they combined their data set with those of the four previous studies by Ars, Sharif, Bolcekova, and Hutter to reach a sample size of 310 patients. It was found that children with OPG were more likely to harbour 5' gene mutations. In addition, the association was stronger in subjects with 5' tertile truncating or nonsense mutations, thus suggesting that the *NF1* mutation may be a predictive factor \[[@B27-cancers-11-01838]\].

However, using stricter inclusion and exclusion criteria, Xu et al. found no significant statistical association between mutations clustering in the 5' tertile and the risk of developing OPG when they analysed 215 NF1 patients (5 from Sun Yatsen University in China and 210 selected from the literature) \[[@B28-cancers-11-01838]\]. Nevertheless, it is interesting to note that patients with mutations involving the cysteine/serine-rich domain of *NF1* were at a higher risk of developing OPG than those with mutations in other regions, whereas those with mutations in the HEAT-like repeat region were at a lower risk. As different mutation types have different effects on protein structure and function, the authors also compared the distribution of the types in the two regions, and found that nonsense mutations were more frequent in the CSRD in the OPG group and splicing site mutations were more frequent in the HLR in the non-OPG group, but these between-region differences were not significant \[[@B28-cancers-11-01838]\].

As recently as 2019, Anastasaki et al. \[[@B29-cancers-11-01838]\] re-examined their previously reported data concerning patients from their institution and retrieved from the literature (a total of 310 patients) and the dataset of Xu et al. (215 patients, 144 of whom were the same as those in the dataset of Anastasaki et al.), and found that mutation clustering in the 5' tertile was significantly different between the patients with and without OPG when their dataset was considered alone (310 patients) or combined with that of Xu (making a total of 381 patients), but not when Xu's dataset was considered alone. In addition, an analysis of their own cohort of 310 patients confirmed the findings of Xu et al., that mutations in the CSRD were significantly positively associated with OPG, whereas mutations in the HLR were negatively associated with OPG, and this difference persisted when the combined dataset of 381 patients (127 with OPG and 254 without) was analysed.

This succession of papers with partially concordant findings about a correlation between OPG and *NF1* mutations located in the first tertile of the gene or in the CSRD prompted us to contribute to the current debate concerning NF1 genotypes and the risk of developing OPG by validating these findings in a large independent series of patients.

Unfortunately, and unexpectedly, our data do not confirm the association reported by Xu et al. and Anastasaki et al., or the original observations of Sharif et al., as we did not find any correlation between the development of OPG and the site (tertile and domain) or type of mutation \[[@B25-cancers-11-01838],[@B27-cancers-11-01838],[@B28-cancers-11-01838],[@B29-cancers-11-01838]\].

The difference may be because of what we consider to be the most important limitation of the previous studies: patient enrolment. The studies by Sharif, Hutter, and Bolcekova were limited by their small sample sizes; in addition, some included familial cases and children under 10 years of age in the non-OPG group (even though the former can clearly carry the same modifier genes and the latter are still at risk of developing an OPG), and patients with whole gene deletions \[[@B25-cancers-11-01838],[@B26-cancers-11-01838]\]. Furthermore, with the aim of reaching a large series with statistical power, Xu and Anastasaki progressively added a limited number of patients to the original cohorts of Sharif, Hutter, and Bolcekova \[[@B27-cancers-11-01838],[@B28-cancers-11-01838],[@B29-cancers-11-01838]\] and, although they filtered the patients retrieved from the literature using stricter inclusion and exclusion criteria before the statistical re-analyses, a bias was generated because the same patients were repeatedly analysed in the various studies.

The strengths of the present study include the fact that it involved a large and completely independent sample of NF1 patients selected on the basis of strict inclusion and exclusion criteria and did not include family cases, patients harbouring a microdeletion, or patients aged \<10 years in the non-OPG group. In addition, our series mainly consists of patients who were genetically analysed by a single laboratory and selected using precise radiological criteria for a diagnosis of OPG. Cases with increased optic nerve tortuosity and nerve or sheath thickening were excluded because it is unclear whether these characteristics are significant in terms of the subsequent development of OPG \[[@B30-cancers-11-01838]\].

In order to achieve the statistical power described by Anastasaki et al., we searched the literature for patients meeting the same inclusion/exclusion criteria as those used to select our institutional cohort. We decided not to select any patients previously included in the studies of Anastasaki, Xu, and the others mentioned above in order to ensure a completely independent cohort.

However, to provide additional data, we combined our cohort with the most recent cohort described by Anastasaki \[[@B29-cancers-11-01838]\] to create a large sample of 690 patients, and performed the same statistical analysis. The results confirmed the absence of a correlation between the position of the NF1 mutation (by tertile and functional domain) and the risk of OPG, thus further strengthening our conclusions ([Tables S1 and S2](#app1-cancers-11-01838){ref-type="app"}).

It is worth noting that some of the patients analysed in our study (those in our institutional cohort and those retrieved from the literature) had different ethnic origins. We think that is another strength of the study as it limits the potential confounding effect of polymorphisms shared by the same ethnic group.

However, our study also has some limitations. The first is that the 30.3% of our OPG patients were retrieved from the literature and we cannot be sure that the same radiological criteria were used in their diagnosis.

In addition, when selecting the patients in the non-OPG group, unlike Hutter et al. \[[@B61-cancers-11-01838]\], we did not consider non-optic gliomas among the exclusion criteria. Hutter et al. probably assumed that gliomas have the same biological basis in NF1 patients regardless of their location, but we believe that the biological basis of optic and non-optic gliomas is probably different because they occur at different patient ages and are histologically different (non-optic gliomas are more aggressive and OPGs are more stable). Moreover, adult patients are at risk of developing non-optic gliomas and, if we had used the same exclusion criterion as Hutter et al., we would only have been able to include patients at low risk; that is, very old patients.

Lastly, it would be very interesting to examine the correlations between site/type of *NF1* mutations and other factors such as tumour size; position in the optic pathway; and, above all, symptomatology, because this could help to clarify why some OPGs behave aggressively and others have a stable and benign course over time; however, this would require a much larger sample of NF1 patients with OPG.

5. Conclusions {#sec5-cancers-11-01838}
==============

Knowing the type and location of *NF1* mutations does not give patients or clinicians any valuable prognostic information regarding the development of OPG.

In order to identify other genotype--phenotype correlations, it is necessary to select extremely large and homogeneous groups of patients on the basis of their genotype or phenotype. Previous examples of recognised genotype--phenotype correlations in NF1 have involved patients with a single recurrent mutation or the deletion of the entire *NF1* gene, who make much more homogeneous groups.

Our findings seem to support the hypothesis that other modifying influences such as modifier genes, as well as epigenetic and environmental factors, are likely to be involved in determining the NF1 phenotype.

The following are available online at <https://www.mdpi.com/2072-6694/11/12/1838/s1>, Table S1: Mutations in *NF1* gene tertiles and the risk of developing OPG in the combined cohort of our and Anastasaki's patients; Table S2: Mutations in different *NF1* gene regions and the risk of developing OPG in the combined cohort of our and Anastasaki's patients.
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![Schematic representation of the tertiles of the neurofibromatosis type 1 (*NF1*) gene and the domains of neurofibromin. CSRD, cysteine/serine-rich domain; TBD, tubulin-binding domain; GRD, GTPase activating protein-related domain; PH, pleckstrin homology-like domain; Sec-14, Sec14-like domain; HLR, HEAT-like repeat regions; NLS, nuclear localisation signal region; CTD, C-terminal domain; SBR, syndecan-binding region.](cancers-11-01838-g001){#cancers-11-01838-f001}

![Distribution of *NFI* gene mutations by tertile and domain in the optic pathway glioma (OPG) group. The horizontal bars indicate two OPG patients with a large deletion involving more than one exon. The vertical red lines indicate the limits of the tertiles.](cancers-11-01838-g002){#cancers-11-01838-f002}

![Distribution of *NF1* gene mutations by tertile and domain in the non-OPG group. The horizontal bars indicate two OPG patients with a large deletion involving more than one exon. The vertical red lines indicate the limits of the tertiles.](cancers-11-01838-g003){#cancers-11-01838-f003}

cancers-11-01838-t001_Table 1

###### 

Clinical data, molecular details, mutation type, and mutation location by tertile and domain.

  ID Code                                           Age   Sex   OPG   DNA Change                                 RNA Change                              Protein Change                  Type   Tertile   Domain
  ------------------------------------------------- ----- ----- ----- ------------------------------------------ --------------------------------------- ------------------------------- ------ --------- ---------
  162                                               60    f     yes   c.1-?\_60+? del                            r.(?)                                   p.(?)                           LD     1         nd
  6                                                 30    f     yes   c.21_22delGG                               r.(?)                                   p.Glu8Metfs\*29                 FS     1         nd
  112                                               15    f     yes   c.60+1G\>A                                 r.(?)                                   p.(?)                           SS     1         nd
  Calì et al. 1 \[[@B38-cancers-11-01838]\]         29    f     yes   c.61-2A\>C                                 r.(?)                                   p.(?)                           SS     1         nd
  8                                                 12    f     yes   c.61-?\_204+?del                           r.61_204del                             p.Leu21_Met68del                LD     1         nd
  24                                                31    f     no    c.61-?\_288+?del                           r.61_288del                             p.Leu21_Gly96del                LD     1         nd
  139                                               6     f     yes   c.61-?\_288+?del                           r.61_288del                             p.Leu21_Gly96del                LD     1         nd
  Bonatti et al. 1 \[[@B37-cancers-11-01838]\]      na    m     yes   c.61-?\_2325+?del                          r.(?)                                   p.Leu21_Glu775del               LD     1         CSRD
  Tsipi et al. 38 \[[@B33-cancers-11-01838]\]       55    na    no    c.86_87delAC                               r.(?)                                   p.His31Tyrfs\*6                 FS     1         nd
  136                                               35    f     no    c.99A\>G                                   r.100_204del                            p.Val34_Met68del                SS     1         nd
  177                                               11    f     yes   c.185dupT                                  r.(?)                                   p.Leu62Phefs\*5                 FS     1         nd
  76                                                42    f     no    c.205_288del                               r.205_288del                            p.Arg69_Gly96del                LD     1         nd
  153                                               21    m     no    c.236T\>G                                  r.(?)                                   p.Leu79\*                       NS     1         nd
  46                                                36    f     yes   c.247C\>T                                  r.(?)                                   p.Gln83\*                       NS     1         nd
  65                                                9     f     yes   c.247delCinsGAGA                           r.(?)                                   p.Gln83delinsGluLys             ID     1         nd
  30                                                53    m     no    c.252delG                                  r.(?)                                   p.Ile85fs\*18                   FS     1         nd
  127                                               59    m     no    c.259_264delTTGGATinsAA                    r.259_264deluuggauinsaa                 p.Leu87Lysfs\*15                FS     1         nd
  109                                               71    f     no    c.288+1delG                                r.288_288del                            p.Gln97Asnfs\*6                 SS     1         nd
  250                                               34    m     no    c.288+5G\>A                                r.205_288del                            p.Arg69_Gly96del                SS     1         nd
  256                                               26    f     no    c.288+5G\>C                                r.(?)                                   p.(?)                           SS     1         nd
  244                                               33    m     no    c.288+1138C\>T                             r.288_289 ins 288+1019_288+1136ins118   p.Gly96_Glu 97ins39aa+fs \*10   SS     1         nd
  Tsipi et al. 114 \[[@B33-cancers-11-01838]\]      7     na    yes   c.350_351insT                              r.(?)                                   p.Cys118Leufs\*9                FS     1         nd
  79                                                35    f     yes   c.479G\>T                                  r.289_479del                            p.Gln97Valfs\*13                SS     1         nd
  31                                                75    f     no    c.484C\>T                                  r.(?)                                   p.Gln162\*                      NS     1         nd
  7                                                 44    m     no    c.493delA                                  r.(?)                                   p.Thr165Leufs\*13               FS     1         nd
  131                                               50    f     no    c.495_498delTGTT                           r.495_498del                            p.Thr166fs\*11                  FS     1         nd
  68                                                28    f     yes   c.495_498delTGTT                           r.495_498del                            p.Thr166fs\*11                  FS     1         nd
  61                                                39    f     no    c.499_502delTGTT                           r.(?)                                   p.Cys167Glnfs\*10               FS     1         nd
  183                                               26    m     no    c.499_502delTGTT                           r.(?)                                   p.Cys167Glnfs\*10               FS     1         nd
  Terzi et al. 23 \[[@B40-cancers-11-01838]\]       na    na    yes   c.499_502delTGTT                           r.(?)                                   p.Cys167Glnfs\*10               FS     1         nd
  Tsipi et al. 90 \[[@B33-cancers-11-01838]\]       15    na    yes   c.501T\>A                                  r.(?)                                   p.Cys167\*                      NS     1         nd
  171                                               29    m     no    c.539T\>G                                  r.539u\>g                               p.Leu180\*                      NS     1         nd
  44                                                57    f     no    c.574C\>T                                  r.574c\>u                               p.Arg192\*                      NS     1         nd
  57                                                44    f     no    c.574C\>T                                  r.574c\>u                               p.Arg192\*                      NS     1         nd
  160                                               17    f     yes   c.574C\>T                                  r.574c\>u                               p.Arg192\*                      NS     1         nd
  188                                               56    f     no    c.586+1G\>T                                r.(?)                                   p.(?)                           SS     1         nd
  180                                               44    m     no    c.586+4dupA                                r.(?)                                   p.(?)                           SS     1         nd
  193                                               46    f     no    c.647_649delTGG                            r.(?)                                   p.Leu216_Glu217delinsGln        ID     1         nd
  175                                               27    f     no    c.615_616delGAinsAT                        r.587_654del                            p.Glu196Glyfs\*12               SS     1         nd
  85                                                42    m     no    c.649delG                                  r.(?)                                   p.Glu217Lysfs\*8                FS     1         nd
  144                                               38    f     no    c.652_653delAAinsG                         r.(?)                                   p.Lys218Glyfs\*7                FS     1         nd
  Tsipi et al. 156 \[[@B33-cancers-11-01838]\]      4     na    yes   c.653_653insA                              r.(?)                                   p.Lys218Argfs\*7                FS     1         nd
  215                                               11    m     no    c.681T\>G                                  r.(?)                                   p.Tyr227\*                      NS     1         nd
  1                                                 25    m     yes   c.801delG                                  r.(?)                                   p.Trp267Cysfs\*14               FS     1         nd
  253                                               59    f     no    c.910C\>T                                  r.(?)                                   p.Arg304\*                      NS     1         nd
  118                                               30    f     no    c.910C\>T                                  r.(?)                                   p.Arg304\*                      NS     1         nd
  129                                               38    m     yes   c.945_946delGCinsAA                        r.889_1062del                           p.Lys297_Lys354del              SS     1         nd
  228                                               15    m     no    c.952_953delGA                             r.(?)                                   p.Glu318fs\*11                  FS     1         nd
  135                                               15    m     yes   c.952_953delGA                             r.(?)                                   p.Glu318fs\*11                  FS     1         nd
  Tsipi et al. 102 \[[@B33-cancers-11-01838]\]      44    na    no    c.968C\>A                                  r.(?)                                   p.Ala323Asp                     MS     1         nd
  224                                               15    m     no    c.980T\>C                                  r.980u\>c                               p.Leu327Pro                     MS     1         nd
  120                                               15    m     yes   c.980T\>C                                  r.980u\>c                               p.Leu327Pro                     MS     1         nd
  212                                               15    f     no    c.998_999insA                              r.998_999insa                           p.Tyr333\*                      FS     1         nd
  199                                               4     f     yes   c.1007G\>A                                 r.(?)                                   p.Trp336\*                      NS     1         nd
  35                                                35    f     no    c.1019_1020delCT                           r.(?)                                   p.Ser340Cysfs\*12               FS     1         nd
  106                                               20    m     no    c.1021_1022delGT                           r.(?)                                   p.Val341Hisfs\*11               FS     1         nd
  Tsipi et al. 78 \[[@B33-cancers-11-01838]\]       15    na    no    c.1022_1023insGA                           r.(?)                                   p.Ile342Thrfs\*35               FS     1         nd
  166                                               na    f     no    c.1062G\>T                                 r.889_1062del                           p.Lys297_Lys354del              SS     1         nd
  105                                               48    f     yes   c.1062+113A\>G                             r.1062_1063ins113                       p.Asn355Valfs\*12               SS     1         nd
  170                                               18    m     no    c.1063-2A\>C                               r.(?)                                   p.(?)                           SS     1         nd
  84                                                44    f     no    c.1122_1125delTCTA                         r.1122_1125del                          p.Asp374Glufs\*2                FS     1         nd
  74                                                36    f     no    c.1140delT                                 r.(?)                                   p.Val381Phefs\*6                FS     1         nd
  Bonatti et al. 15 \[[@B37-cancers-11-01838]\]     na    m     yes   c.1144delT                                 r.(?)                                   p.Ser382Leufs\*5                FS     1         nd
  Tsipi et al. 126 \[[@B33-cancers-11-01838]\]      28    na    no    c.1182_1183insT                            r.(?)                                   p.Lys395\*                      FS     1         nd
  59                                                45    f     no    c.1186-1G\>C                               r.1186_1200del                          p.Ile396_Gln400del              SS     1         nd
  51                                                9     m     yes   c.1246C\>T                                 r.1246c\>u                              p.Arg416\*                      NS     1         nd
  208                                               10    f     no    c.1246C\>T                                 r.1246c\>u                              p.Arg416\*                      NS     1         nd
  238                                               20    m     no    c.1249delA                                 r.(?)                                   p.Ile417Serfs\*56               FS     1         nd
  39                                                21    m     yes   c.1259_1260insT                            r.(?)                                   p.Ser421fs\*8                   FS     1         nd
  Tsipi et al. 112 \[[@B33-cancers-11-01838]\]      43    m     yes   c.1275G\>A                                 r.(?)                                   p.Trp425\*                      NS     1         nd
  81                                                56    m     no    c.1315C\>T                                 r.(?)                                   p.Leu439Phe                     MS     1         nd
  240                                               40    f     yes   c.1318C\>T                                 r.1318c\>u                              p.Arg440\*                      NS     1         nd
  60                                                66    m     no    c.1318C\>T                                 r.1318c\>u                              p.Arg440\*                      NS     1         nd
  237                                               4     m     yes   c.1381C\>T                                 r.1381c\>u                              p.Arg461\*                      NS     1         nd
  206                                               4     m     yes   c.1381C\>T                                 r.1381c\>u                              p.Arg461\*                      NS     1         nd
  233                                               12    m     no    c.1392+1G\>A                               r.(?)                                   p.(?)                           SS     1         nd
  178                                               31    m     no    c.1392+1G\>T                               r.(?)                                   p.Ser421_Pro464del              SS     1         nd
  58                                                16    f     no    c.1393-3_1393-2delTA                       r.1393_1527del                          p.Ser465_Cys509del              SS     1         nd
  124                                               53    f     no    c.1393-?\_2325+?del                        r.(?)                                   p.Ser465_Glu775del              LD     1         CSRD
  17                                                40    f     no    c.1399_1400insA                            r.(?)                                   p.Thr467Asnfs\*3                FS     1         nd
  200                                               9     f     yes   c.1453G\>T                                 r.(?)                                   p.Glu485\*                      NS     1         nd
  Bonatti et al. 22 \[[@B37-cancers-11-01838]\]     na    m     yes   c.1462delA                                 r.(?)                                   p.Ser488Alafs\*10               FS     1         nd
  91                                                49    f     no    c.1466A\>G                                 r.1466_1527del                          p.Tyr489\*                      SS     1         nd
  96                                                13    f     yes   c.1466A\>G                                 r.1466_1527del                          p.Tyr489\*                      SS     1         nd
  Tsipi et al. 87 \[[@B33-cancers-11-01838]\]       8     m     yes   c.1466A\>G                                 r.1466_1527del                          p.Tyr489\*                      SS     1         nd
  126                                               43    f     no    c.1466A\>G                                 r.1466_1527del                          p.Tyr489\*                      SS     1         nd
  172                                               46    m     no    c.1466A\>G                                 r.1466_1527del                          p.Tyr489\*                      SS     1         nd
  221                                               14    f     no    c.1466A\>G                                 r.1466_1527del                          p.Tyr489\*                      SS     1         nd
  Terzi et al. 679 \[[@B40-cancers-11-01838]\]      na    na    yes   c.1525_1526insT                            r.(?)                                   p.Cys509Leufs\*2                FS     1         nd
  104                                               61    m     no    c.1527+5G\>A                               r.1393_1527del                          p.Ser465_Cys509del45            SS     1         nd
  173                                               19    f     yes   c.1527+675C\>T                             r.1527_1528ins116                       p.Asp510Argfs17                 SS     1         nd
  187                                               39    f     no    c.1541_1542delAG                           r.(?)                                   p.Gln514fs\*21                  FS     1         nd
  157                                               21    f     no    c.1542delG                                 r.(?)                                   p.Lys514fs\*10                  FS     1         nd
  145                                               5     m     yes   c.1549G\>T                                 r.1549g\>u                              p.Glu517\*                      NS     1         nd
  163                                               10    m     yes   c.1603C\>T                                 r.(?)                                   p.Gln535\*                      NS     1         nd
  93                                                19    m     yes   c.1658A\>G                                 r.1658a\>g                              p.His553Arg                     MS     1         CSRD
  Tsipi et al. 127 \[[@B33-cancers-11-01838]\]      5     na    yes   c.1722-3C\>A                               r.(?)                                   p.(?)                           SS     1         CSRD
  176                                               18    f     no    c.1722C\>G                                 r.(?)                                   p.Ser574Arg                     MS     1         CSRD
  Tsipi et al. 98 \[[@B33-cancers-11-01838]\]       12    m     yes   c.1724C\>A                                 r.(?)                                   p.Ser575\*                      NS     1         CSRD
  Tsipi et al. 44 \[[@B33-cancers-11-01838]\]       58    na    yes   c.1755_1758delAACT                         r.(?)                                   p.Thr586Valfs\*18               FS     1         CSRD
  89                                                3     m     yes   c.1756_1759delACTA                         r.(?)                                   p.Thr586Valfs\*18               FS     1         CSRD
  169                                               18    f     yes   c.1756_1759delACTA                         r.(?)                                   p.Thr586Valfs\*18               FS     1         CSRD
  226                                               18    f     no    c.1830_1833delTCTT                         r.(?)                                   p.Leu612Lysfs\*18               FS     1         CSRD
  98                                                55    m     no    c.1840_1841insTTTT                         r.(?)                                   p.Asn614llefs\*2                FS     1         CSRD
  14                                                38    m     no    c.1885G\>A                                 r.1885_1925del                          p.Gln616Glyfs\*4                SS     1         CSRD
  101                                               4     m     yes   c.1885G\>A                                 r.1885_1925del                          p.Gln616Glyfs\*4                SS     1         CSRD
  220                                               12    m     no    c.1885G\>A                                 r.1885_1925del                          p.Gln616Glyfs\*4                SS     1         CSRD
  Bonatti et al. 34 \[[@B37-cancers-11-01838]\]     na    m     yes   c.1889T\>A                                 r.(?)                                   p.Val630Glu                     MS     1         CSRD
  143                                               16    f     yes   c.1907_1908delCT                           r.1907_1908del                          p.Ser636\*                      FS     1         CSRD
  125                                               36    f     no    c.2019delC                                 r.(?)                                   p.Cys673\*                      FS     1         CSRD
  Tsipi et al. 50 \[[@B33-cancers-11-01838]\]       29    na    no    c.2033dupC                                 r.2033dupc                              p.Ile679Aspfs\*21               FS     1         CSRD
  181                                               41    f     no    c.2033dupC                                 r.2033dupc                              p.Ile679Aspfs\*21               FS     1         CSRD
  94                                                41    m     no    c.2033dupC                                 r.2033dupc                              p.Ile679Aspfs\*21               FS     1         CSRD
  97                                                12    f     yes   c.2041C\>T                                 r.2041c\>u                              p.Arg681\*                      NS     1         CSRD
  254                                               63    m     no    c.2041C\>T                                 r.2041c\>u                              p.Arg681\*                      NS     1         CSRD
  203                                               8     f     yes   c.2041C\>T                                 r.2041c\>u                              p.Arg681\*                      NS     1         CSRD
  156                                               72    m     no    c.2041C\>T                                 r.2041c\>u                              p.Arg681\*                      NS     1         CSRD
  207                                               13    m     no    c.2041C\>T                                 r.2041c\>u                              p.Arg681\*                      NS     1         CSRD
  102                                               29    f     yes   c.2084_2085delTG                           r.(?)                                   p.Trp696Glufs\*3                FS     1         CSRD
  115                                               59    m     no    c.2106delT                                 r.(?)                                   p.Val703Phefs\*45               FS     1         CSRD
  161                                               13    f     yes   c.2131delC                                 r.(?)                                   p.Arg711Alafs\*37               FS     1         CSRD
  245                                               55    f     no    c.2251+1G\>A                               r.2002_2251del                          p.Asp668Glufs\*9                SS     1         CSRD
  168                                               69    m     no    c.2297T\>G                                 r.(?)                                   p.Ile766Ser                     MS     1         CSRD
  26                                                52    m     no    c.2325G\>C                                 r.2252_2325del                          p.Arg752Leufs\*17               SS     1         CSRD
  Tsipi et al. 151 \[[@B33-cancers-11-01838]\]      9     m     yes   c.2326-3T\>G                               r.(?)                                   p.(?)                           SS     1         CSRD
  22                                                40    m     no    c.2329T\>A                                 r.(?)                                   p.Trp777Arg                     MS     1         CSRD
  236                                               12    m     no    c.2352G\>C                                 r.(?)                                   p.Trp784Cys                     MS     1         CSRD
  16                                                37    f     no    c.2356delC                                 r.(?)                                   p.Gln786fs\*5                   FS     1         CSRD
  100                                               32    f     no    c.2409+1insCCC                             r.2326_2409del                          p.Ala776_Gln803del              SS     1         CSRD
  128                                               59    m     no    c.2409+1G\>T                               r.2326_2409del                          p.Ala776_Gln803del              SS     1         CSRD
  235                                               12    f     no    c.2409+1G\>T                               r.2326_2409del                          p.Ala776_Gln803del              SS     1         CSRD
  154                                               29    f     yes   c.2410-18C\>G                              r.2409_2410ins2410-17_2410-1            p.Gln803fs\*23                  SS     1         CSRD
  Calì et al. 25 \[[@B38-cancers-11-01838]\]        7     m     yes   c.2446C\>T                                 r.(?)                                   p.Arg816\*                      NS     1         CSRD
  55                                                50    f     no    c.2492_2493dupCA                           r.2492_2493dupca                        p.Asp832Glnfs\*10               FS     1         CSRD
  227                                               13    f     no    c.2537_2538ins TCAACATGACTGGCTTCCTTTGTGC   r.2537_2538ins25                        p.Leu847Glnfs\*26               FS     1         CSRD
  182                                               44    f     no    c.2540T\>C                                 r.2540u\>c                              p.Leu847Pro                     MS     1         CSRD
  73                                                21    f     yes   c.2540T\>C                                 r.2540u\>c                              p.Leu847Pro                     MS     1         CSRD
  90                                                18    m     no    c.2571delTinsAG                            r.(?)                                   p.Ser858Leufs\*7                FS     1         CSRD
  231                                               18    m     no    c.2669delC                                 r.2669del                               p.Pro890Leufs\*12               FS     1         CSRD
  5                                                 21    m     yes   c.2674_2674delA                            r.2674_2674del                          p.Ser892Alafs\*10               FS     1         CSRD
  149                                               18    m     no    c.2693T\>C                                 r.(?)                                   p.Leu898Pro                     MS     1         CSRD
  67                                                51    f     no    c.2730_2731insAAGTGGGA                     r.(?)                                   p.Leu911Lysfs\*16               FS     1         nd
  122                                               45    f     no    c.2850+1G\>T                               r.2618_2850del                          p.Lys874Phefs\*4                SS     1         CSRD
  15                                                7     m     yes   c.2850G\>A                                 r.(?)                                   p.Lys874Phefs\*4                SS     1         CSRD
  Tsipi et al. 124 \[[@B33-cancers-11-01838]\]      11    na    yes   c.2858T\>A                                 r.(?)                                   p.Leu953\*                      NS     2         nd
  246                                               45    f     no    c.2915T\>C                                 r.2915u\>c                              p.Leu972Pro                     MS     2         nd
  158                                               12    m     yes   c.2990+1G\>T                               r.(?)                                   p.(?)                           SS     2         nd
  150                                               38    m     yes   c.2990+5G\>C                               r.2851_2990del                          p.Leu952Cysfs\*22               SS     2         nd
  142                                               35    f     no    c.2991-2A\>G                               r.(?)                                   p.Tyr998_Arg1038del             SS     2         nd
  190                                               42    f     no    c.3047_3048delGT                           r.(?)                                   p.Cys1016Serfs\*4               FS     2         nd
  251                                               25    m     no    c.3062_3063insGT                           r.(?)                                   p.Met1022\*                     FS     2         nd
  Tsipi et al. 170 \[[@B33-cancers-11-01838]\]      11    na    no    c.3076A\>T                                 r.(?)                                   p.Arg1026\*                     NS     2         nd
  223                                               14    f     no    c.3104T\>G                                 r.3104u\>g                              p.Met1035Arg                    MS     2         nd
  Trevisson et al. I \[[@B35-cancers-11-01838]\]    41    f     no    c.3112A\>G                                 r.(?)                                   p.Arg1038Gly                    MS     2         nd
  Trevisson et al. II \[[@B35-cancers-11-01838]\]   30    f     no    c.3112A\>G                                 r.(?)                                   p.Arg1038Gly                    MS     2         nd
  10                                                14    m     yes   c.3168_3169insTA                           r.(?)                                   p.Ala1057\*                     FS     2         nd
  29                                                8     f     yes   c.3198-2A\>G                               r.3198_3199del                          p.Asp1067fs\*20                 SS     2         nd
  Lin et al. 1 \[[@B41-cancers-11-01838]\]          53    f     no    c.3236_3240dupTTCTA                        r.(?)                                   p.Ala1081Phefs\*2               FS     2         nd
  134                                               17    f     no    c.3311T\>G                                 r.3311_3314del                          p.Leu1104Hisfs\*7               SS     2         TBD
  164                                               28    f     no    c.3456_3459delACTC                         r.3456_3459del                          p.Leu1153Metfs\*4               FS     2         TBD
  99                                                22    f     yes   c.3496+1G\>A                               r.(?)                                   p.Tyr1106Leufs\*28              SS     2         TBD
  217                                               12    f     no    c.3520C\>T                                 r.(?)                                   p.Gln1174\*                     NS     2         TBD
  38                                                49    m     no    c.3574G\>T                                 r.(?)                                   p.Glu1192\*                     NS     2         TBD
  138                                               33    f     no    c.3610C\>G                                 r.(?)                                   p.Arg1204Gly                    MS     2         GRD
  18                                                46    f     no    c.3708+1G\>C                               r.3497_3708del                          p.Leu1167\*                     SS     2         TBD
  Ulusal et al. 7 \[[@B34-cancers-11-01838]\]       57    f     yes   c.3709-2A\>G                               r.3709_3718del                          p.Asp1237Leufs\*26              SS     2         GRD
  13                                                31    f     yes   c.3721C\>T                                 r.(?)                                   p.Arg1241\*                     NS     2         GRD
  241                                               42    f     yes   c.3721C\>T                                 r.(?)                                   p.Arg1241\*                     NS     2         GRD
  110                                               55    m     no    c.3739_3742delTGTT                         r.(?)                                   p.Phe1247Ilefs\*18              FS     2         GRD
  42                                                16    m     yes   c.3826C\>T                                 r.3826c\>u                              p.Arg1276\*                     NS     2         GRD
  165                                               35    m     no    c.3826C\>T                                 r.3826c\>u                              p.Arg1276\*                     NS     2         GRD
  232                                               19    f     no    c.3826C\>T                                 r.3826c\>u                              p.Arg1276\*                     NS     2         GRD
  243                                               50    m     yes   c.3826C\>T                                 r.3826c\>u                              p.Arg1276\*                     NS     2         GRD
  191                                               43    f     yes   c.3826_3828delCGAinsTACT                   r.3826_3828delcgainsuacu                p.Arg1276Tyrfs\*8               FS     2         GRD
  209                                               11    m     no    c.3827G\>A                                 r.3827g\>a                              p.Arg1276Gln                    MS     2         GRD
  54                                                61    m     yes   c.3827G\>C                                 r.(?)                                   p.Arg1276Pro                    MS     2         GRD
  49                                                22    m     yes   c.3844delA                                 r.(?)                                   p.Ser1282Valfs\*3               FS     2         GRD
  155                                               25    m     yes   c.3847delA                                 r.(?)                                   p.Ile1284\*                     FS     2         GRD
  88                                                45    f     no    c.3859delT                                 r.(?)                                   p.Phe1287Serfs\*22              FS     2         GRD
  Tsipi et al. 115 \[[@B33-cancers-11-01838]\]      6     na    yes   c.3870_3871insTAG                          r.(?)                                   p.Val1291\*                     NS     2         GRD
  50                                                46    m     no    c.3888T\>G                                 r.(?)                                   p.Tyr1296\*                     NS     2         GRD
  70                                                6     f     yes   c.3916C\>T                                 r.3916c\>u                              p.Arg1306\*                     NS     2         GRD
  36                                                59    m     no    c.3916C\>T                                 r.3916c\>u                              p.Arg1306\*                     NS     2         GRD
  167                                               64    f     no    c.3941G\>A                                 r.(?)                                   p.Trp1314\*                     NS     2         GRD
  192                                               26    m     no    c.3974+1G\>A                               r.(?)                                   p.(?)                           SS     2         GRD
  83                                                40    f     no    c.3974+1G\>T                               r.3871_3974del                          p.Tyr1292Argfs\*8               SS     2         GRD
  151                                               40    m     no    c.3974+2T\>G                               r.(?)                                   p.(?)                           SS     2         GRD
  255                                               44    f     no    c.3975-2A\>G                               r.3975_3979delguuag                     p.Leu1326Thrfs\*6               SS     2         GRD
  117                                               16    m     yes   c.3975-?\_4110+?                           r.(?)                                   p.Leu1326Trpfs\*14              LD     2         GRD
  219                                               11    m     no    c.3983_3986delCATC                         r.3983_3986del                          p.Pro1328Glnfs\*14              FS     2         GRD
  77                                                67    f     yes   c.3989_3992delAGAG                         r.(?)                                   p.Glu1330Alafs\*12              FS     2         GRD
  132                                               46    f     no    c.4054delA                                 r.(?)                                   p.Ser1352Valfs\*3               FS     2         GRD
  9                                                 38    m     yes   c.4084C\>T                                 r.(?)                                   p.Arg1362\*                     NS     2         GRD
  21                                                10    f     yes   c.4084C\>T                                 r.(?)                                   p.Arg1362\*                     NS     2         GRD
  116                                               10    f     yes   c.4084C\>T                                 r.(?)                                   p.Arg1362\*                     NS     2         GRD
  Tsipi et al. 106 \[[@B33-cancers-11-01838]\]      6     f     yes   c.4084C\>T                                 r.(?)                                   p.Arg1362\*                     NS     2         GRD
  113                                               45    m     no    c.4084C\>T                                 r.(?)                                   p.Arg1362\*                     NS     2         GRD
  140                                               30    f     no    c.4084C\>T                                 r.(?)                                   p.Arg1362\*                     NS     2         GRD
  179                                               5     m     yes   c.4110+1G\>C                               r.(?)                                   p.(?)                           SS     2         GRD
  Tsipi et al. 96 \[[@B33-cancers-11-01838]\]       54    na    no    c.4134C\>T                                 r.(?)                                   p.Gln1378\*                     NS     2         GRD
  189                                               31    f     no    c.4154delG                                 r.4154del                               p.Gly1385Glufs\*22              FS     2         GRD
  Tsipi et al. 161 \[[@B33-cancers-11-01838]\]      11    na    yes   c.4174G\>C                                 r.(?)                                   p.Arg1391Thr                    MS     2         GRD
  75                                                25    f     yes   c.4267A\>G                                 r.4267a\>g                              p.Lys1423Glu                    MS     2         GRD
  Tsipi et al. 177 \[[@B33-cancers-11-01838]\]      6     m     yes   c.4269+1delG                               r.(?)                                   p.(?)                           SS     2         GRD
  Bonatti et al. 62 \[[@B37-cancers-11-01838]\]     na    m     yes   c.4269+1G\>C                               r.4111_4269del                          p.Val1371_Lys1423del            SS     2         GRD
  137                                               47    m     no    c.4353delT                                 r.(?)                                   p.Phe1451Leufs\*11              FS     2         GRD
  92                                                40    f     no    c.4402_4406delAGTGA                        r.4402_4406del                          p.Ser1468Cysfs\*5               FS     2         GRD
  72                                                5     m     yes   c.4435A\>G                                 r.4368_4435del                          p.Phe1457\*                     SS     2         GRD
  Tsipi et al. 95 \[[@B33-cancers-11-01838]\]       6     na    yes   c.4474G\>A                                 r.(?)                                   p.Trp1491\*                     NS     2         GRD
  147                                               46    m     no    c.4515-1G\>A                               r.(?)                                   p.(?)                           SS     2         GRD
  196                                               56    m     yes   c.4537C\>T                                 r.4537c\>u                              p.Arg1513\*                     NS     2         GRD
  211                                               10    m     no    c.4537C\>T                                 r.4537c\>u                              p.Arg1513\*                     NS     2         GRD
  27                                                49    f     no    c.4537C\>T                                 r.4537c\>u                              p.Arg1513\*                     NS     2         GRD
  47                                                17    m     no    c.4577delG                                 r.(?)                                   p.Gly1526Valfs\*27              FS     2         GRD
  123                                               34    m     no    c.4606dupA                                 r.(?)                                   p.Thr1536Asnfs\*7               FS     2         nd
  34                                                48    f     no    c.4630delA                                 r.(?)                                   p.Thr1544Profs\*9               FS     2         nd
  37                                                14    f     yes   c.4684G\>T                                 r.4684g\>u                              p.Glu1562\*                     NS     2         Sec14
  146                                               19    m     yes   c.4817T\>A                                 r.(?)                                   p.Val1606Asp                    MS     2         Sec14
  213                                               14    m     no    c.4867G\>C                                 r.(?)                                   p.Asp1623His                    MS     2         Sec14
  Tsipi et al. 68 \[[@B33-cancers-11-01838]\]       11    na    no    c.4959G\>A                                 r.(?)                                   p.Val1653Ile                    MS     2         Sec14
  64                                                18    m     yes   c.4983_4984dupT                            r.(?)                                   p.Asn1662\*                     FS     2         Sec14
  121                                               23    f     yes   c.5028delG                                 r.(?)                                   p.Thr1677Leufs\*12              FS     2         Sec14
  202                                               7     f     yes   c.5047A\>T                                 r.(?)                                   p.Lys1683\*                     NS     2         Sec14
  32                                                50    f     no    c.5154_5157dupATTC                         r.(?)                                   p.His1720Ilefs\*17              FS     2         PH
  43                                                17    f     no    c.5170A\>T                                 r.(?)                                   p.Lys1724\*                     NS     2         PH
  Tsipi et al. 39 \[[@B33-cancers-11-01838]\]       35    na    no    c.5209T\>G                                 r.(?)                                   p.Val1736Gly                    MS     2         PH
  Terzi et al. 320 \[[@B40-cancers-11-01838]\]      na    na    yes   c.5224C\>T                                 r.(?)                                   p.Gln1742\*                     NS     2         PH
  Terzi et al. 325 \[[@B40-cancers-11-01838]\]      na    na    yes   c.5224C\>T                                 r.(?)                                   p.Gln1742\*                     NS     2         PH
  25                                                20    m     no    c.5242C\>T                                 r.(?)                                   p.Arg1748\*                     NS     2         PH
  152                                               5     m     yes   c.5276delA                                 r.5276del                               p.Asn1759Metfs\*14              FS     2         PH
  130                                               44    f     no    c.5353C\>T                                 r.(?)                                   p.Gln1785\*                     NS     2         PH
  Tsipi et al. 129 \[[@B33-cancers-11-01838]\]      3     m     yes   c.5382C\>T                                 r.(?)                                   p.Gln1794\*                     NS     2         PH
  234                                               13    m     no    c.5425C\>T                                 r.(?)                                   p.Arg1809Cys                    MS     2         PH
  214                                               10    f     no    c.5426G\>C                                 r.(?)                                   p.Arg1809Pro                    MS     2         PH
  Tsipi et al.89 \[[@B33-cancers-11-01838]\]        30    m     yes   c.5429G\>A                                 r.(?)                                   p.Trp1810\*                     NS     2         PH
  41                                                30    f     yes   c.5471insT                                 r.(?)                                   p.Lys1823Asnfs\*18              FS     2         nd
  111                                               19    f     no    c.5483A\>T                                 r.(?)                                   p.Asp1828Val                    MS     2         HLR
  230                                               10    m     no    c.5520T\>G                                 r.5520u\>g                              p.Asn1840Lys                    MS     2         HLR
  133                                               10    m     yes   c.5543T\>A                                 r.(?)                                   p.Leu1848\*                     NS     2         HLR
  Tsipi et al. 46 \[[@B33-cancers-11-01838]\]       28    m     yes   c.5546G\>A                                 r.5206_5546del                          p.Gly1737fs\*4                  SS     2         PH
  107                                               40    f     no    c.5546G\>A                                 r.5206_5546del                          p.Gly1737fs\*4                  SS     2         PH
  Tsipi et al. 125 \[[@B33-cancers-11-01838]\]      9     f     yes   c.5546+1G\>A                               r.5206_5546del                          p.Gly1737fs\*4                  SS     2         PH
  62                                                39    f     no    c.5546+5G\>C                               r.(?)                                   p.(?)                           SS     2         PH
  45                                                19    f     yes   c.5594T\>G                                 r.5594u\>g                              p.Leu1865\*                     NS     2         HLR
  48                                                33    m     no    c.5624C\>G                                 r.(?)                                   p.Ser1875\*                     NS     2         HLR
  242                                               24    m     yes   c.5630delT                                 r.(?)                                   p.Leu1877Tyrfs\*27              FS     2         HLR
  222                                               16    f     no    c.5681T\>C                                 r.5681u\>c                              p.Leu1894Pro                    MS     2         HLR
  247                                               52    f     no    c.5750-177A\>C                             r.5749_5750ins5750-174_5750-108         p.Ser1917Argfs\*25              SS     2         HLR
  28                                                14    f     yes   c.5815delT                                 r.(?)                                   p.Cys1939Aspfs\*19              FS     3         HLR
  205                                               14    f     yes   c.5839C\>T                                 r.5839c\>u                              p.Arg1947\*                     NS     3         HLR
  3                                                 42    m     no    c.5839C\>T                                 r.5839c\>u                              p.Arg1947\*                     NS     3         HLR
  23                                                12    m     yes   c.5839C\>T                                 r.5839c\>u                              p.Arg1947\*                     NS     3         HLR
  Tsipi et al. 144 \[[@B33-cancers-11-01838]\]      12    f     yes   c.5839C\>T                                 r.5839c\>u                              p.Arg1947\*                     NS     3         HLR
  Ulusal et al. 10 \[[@B34-cancers-11-01838]\]      7     m     yes   c.5839C\>T                                 r.5839c\>u                              p.Arg1947\*                     NS     3         HLR
  248                                               35    m     no    c.5839C\>T                                 r.5839c\>u                              p.Arg1947\*                     NS     3         HLR
  159                                               17    m     yes   c.5851_5852insA                            r.(?)                                   p.Thr1951Asnfs\*5               FS     3         HLR
  174                                               49    f     no    c.5890G\>T                                 r.(?)                                   p.Glu1964\*                     NS     3         HLR
  114                                               23    m     no    c.5943G\>T                                 r.(?)                                   p.Gln1891His                    MS     3         HLR
  33                                                22    f     no    c.5944-1G\>T                               r.5944_5950delauuacag                   p.Thr1983Lysfs\*6               SS     3         HLR
  Tsipi et al. 79 \[[@B33-cancers-11-01838]\]       37    na    no    c.6110_6110delT                            r.(?)                                   p.Ile2037Metfs\*12              FS     3         HLR
  Bonatti et al. 85 \[[@B37-cancers-11-01838]\]     na    f     yes   c.6134delC                                 r.(?)                                   p.Thr2045Ilefs\*4               FS     3         HLR
  78                                                41    f     no    c.6278delG                                 r.6278del                               p.Gly2093Valfs\*36              FS     3         HLR
  119                                               29    m     no    c.6346_6347insA                            r.(?)                                   p.Ser2116Tyrfs\*6               FS     3         HLR
  4                                                 42    m     no    c.6364+2T\>A                               r.(?)                                   p.(?)                           SS     3         HLR
  201                                               12    f     yes   c.6365-2A\>G                               r.6365_6579del                          p.Glu2122Glyfs\*27              SS     3         HLR
  Bonatti et al. 90 \[[@B37-cancers-11-01838]\]     na    f     yes   c.6389_6393delTCAGTinsA                    r.(?)                                   p.Leu2130Hisfs\*2               FS     3         HLR
  186                                               47    f     no    c.6477delC                                 r.6477del                               p.Ser2160Valfs\*19              FS     3         HLR
  11                                                60    f     no    c.6641+1G\>A                               r.6580_6641del                          p.Ala2194Ilefs\*6               SS     3         HLR
  239                                               24    f     yes   c.6641+1G\>T                               r.6580_6641del                          p.Ala2194Ilefs\*6               SS     3         HLR
  Stella et al.1 \[[@B39-cancers-11-01838]\]        2     f     yes   c.6687_6689delTGT                          r.(?)                                   p.Val2230del                    ID     3         HLR
  148                                               55    f     no    c.6688delG                                 r.(?)                                   p.Val2230Serfs\*14              FS     3         HLR
  80                                                8     f     yes   c.6709C\>T                                 r.6709c\>u                              p.Arg2237\*                     NS     3         HLR
  86                                                43    m     no    c.6709C\>T                                 r.6709c\>u                              p.Arg2237\*                     NS     3         HLR
  108                                               59    f     no    c.6709C\>T                                 r.6709c\>u                              p.Arg2237\*                     NS     3         HLR
  249                                               71    m     no    c.6709C\>T                                 r.6709c\>u                              p.Arg2237\*                     NS     3         HLR
  204                                               3     m     yes   c.6709C\>T                                 r.6709c\>u                              p.Arg2237\*                     NS     3         HLR
  197                                               5     f     yes   c.6755A\>G                                 r.6642_6756del                          p.Phe2215Hisfs\*6               SS     3         HLR
  216                                               10    f     no    c.6756+11C\>T                              r.6642_6756del                          p.Phe2215Hisfs\*6               SS     3         HLR
  210                                               12    f     no    c.6756+1G\>T                               r.(?)                                   p.(?)                           SS     3         HLR
  198                                               3     m     yes   c.6770_6771insG                            r.6770_6771insg                         p.Cys2257Trpfs\*6               FS     3         HLR
  63                                                55    f     yes   c.6789_6792delTTAC                         r.(?)                                   p.Tyr2264Glnfs\*4               FS     3         HLR-CTD
  194                                               28    m     no    c.6789_6792delTTAC                         r.(?)                                   p.Tyr2264Glnfs\*4               FS     3         HLR-CTD
  Tsipi et al. 135 \[[@B33-cancers-11-01838]\]      17    f     yes   c.6791_6792insA                            r.(?)                                   p.Tyr2264\*                     FS     3         HLR-CTD
  20                                                45    f     no    c.6791_6792insA                            r.(?)                                   p.Tyr2264\*                     FS     3         HLR-CTD
  53                                                29    m     no    c.6792C\>A                                 r.6757_6858del                          p.Ala2253_Lys 2286del           SS     3         HLR-CTD
  87                                                54    m     no    c.6792C\>A                                 r.6757_6858del                          p.Ala2253_Lys 2286del           SS     3         HLR-CTD
  184                                               9     f     yes   c.6792C\>A                                 r.6757_6858del                          p.Ala2253_Lys 2286del           SS     3         HLR-CTD
  12                                                42    m     yes   c.6834delC                                 r.(?)                                   p.Thr2279Asnfs\*20              FS     3         HLR-CTD
  185                                               4     f     yes   c.6858+3A\>T                               r.6757_6858del                          p.Ala2253_Lys2286del            SS     3         HLR-CTD
  66                                                46    f     no    c.6999+1G\>C                               r.(?)                                   p.(?)                           SS     3         HLR-CTD
  2                                                 25    f     no    c.7096_7101delAACTTT                       r.7096_7101del                          p.Asn2366_Phe2367del            ID     3         HLR-CTD
  82                                                24    m     yes   c.7096_7101delAACTTT                       r.7096_7101del                          p.Asn2366_Phe2367del            ID     3         HLR-CTD
  69                                                22    m     no    c.7186_7188delCTA                          r.(?)                                   p.Leu2396del                    ID     3         HLR-CTD
  52                                                32    f     yes   c.7192_7193delCT                           r.(?)                                   p.Leu2398Glyfs\*2               FS     3         HLR-CTD
  Tsipi et al. 128 \[[@B33-cancers-11-01838]\]      5     m     yes   c.7285C\>T                                 r.(?)                                   p.Arg2429\*                     NS     3         CTD
  252                                               54    m     no    c.7337C\>A                                 r.(?)                                   p.Ser2446\*                     NS     3         CTD
  195                                               3     f     yes   c.7345_7346delAA                           r.7345_7346del                          p.Asn2449Cysfs\*12              FS     3         CTD
  225                                               12    m     no    c.7486C\>T                                 r.7486c\>u                              p.Arg2496\*                     NS     3         CTD
  Calì et al. 76 \[[@B38-cancers-11-01838]\]        12    f     yes   c.7486C\>T                                 r.7486c\>u                              p.Arg2496\*                     NS     3         CTD
  218                                               12    f     no    c.7580_7581dupA                            r.(?)                                   p.Ser2528Ilefs\*7               FS     3         CTD
  95                                                26    m     no    c.7619C\>G                                 r.(?)                                   p.Ser2540\*                     NS     3         CTD-NLS
  Micaglio et al. \[[@B36-cancers-11-01838]\]       23    m     no    c.7686delG                                 r.(?)                                   p.Ile2563fs\*40                 FS     3         CTD
  229                                               11    m     no    c.7703delA                                 r.(?)                                   p.Gln2568Argfs\*35              FS     3         CTD
  19                                                10    m     yes   c.7720delA                                 r.(?)                                   p.Val2575Phefs\*28              FS     3         CTD
  Tsipi et al. 162 \[[@B33-cancers-11-01838]\]      7     na    yes   c.7725_7726insG                            r.(?)                                   p.Ser2576Valfs\*4               FS     3         CTD
  40                                                20    f     no    c.7806+1G\>A                               r.(?)                                   p.(?)                           SS     3         CTD
  56                                                27    f     no    c.7993C\>T                                 r.7993c\>u                              p.Gln2665\*                     NS     3         CTD-SBR
  141                                               20    m     no    c.8111delC                                 r.(?)                                   p.Pro2704Glnfs\*14              FS     3         CTD-SBR
  71                                                16    m     yes   c.8332G\>A                                 r.8332g\>a                              p.Val2778Ile                    MS     3         CTD

ID code: simple numbers refer to the patients in our cohort; the patients retrieved from the literature are shown using the name of the first author and the code assigned in the original article; na = not available; nd = no domain; f = female; m = male. OPG, optic pathway glioma; CSRD, cysteine/serine-rich domain; TBD, tubulin-binding domain; GRD, GTPase activating protein-related domain; PH, pleckstrin homology-like domain; HLR, HEAT-like repeat regions; Sec-14, Sec14-like domain; CTD, C-terminal domain; NLS, nuclear localisation signal region; SBR, syndecan-binding region; NS, nonsense mutation; FS, frameshift mutation; MS, missense mutation; ID, inframe mutation; SS, splicing mutation; LD, large deletion.
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###### 

Mutations in *NF1* gene tertiles and the risk of developing OPG.

  --------------------------------------------------------------------------------------------------------------
  Tertile          OPG *n* (%)\   Non-OPG *n* (%)\   *p*-Value \*   OR (95% CI)        *p*-Value \*\*   Total\
                   *n* = 132      *n* = 177                                                             Number
  ---------------- -------------- ------------------ -------------- ------------------ ---------------- --------
  5′ tertile       57 (43.2)      87 (49.2)          0.29           0.28 (0.5--1.23)   0.29             144

  Middle tertile   47 (35.6)      57 (32.2)          0.53           1.16 (0.72--1.8)   0.53             104

  3′ tertile       28 (21.2)      33 (18.6)          0.57           1.17 (0.66--2.0)   0.57             61
  --------------------------------------------------------------------------------------------------------------

Differences in the frequency of mutations in the different tertiles of the *NF1* gene between the OPG and the non-OPG group. \* Chi-squared test; \*\* logistic regression. OR, odds ratio; CI, confidence interval.
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###### 

Mutations in different *NF1* gene regions and the risk of developing OPG.

  ---------------------------------------------------------------------------------------------------------
  Regions    OPG *n* (%)\   Non-OPG *n* (%)\   *p*-Value \*   OR (95% CI)         *p*-Value \*\*   Total\
             *n* = 132      *n* = 177                                                              Number
  ---------- -------------- ------------------ -------------- ------------------- ---------------- --------
  CSRD       20 (15.2)      30 (16.9)          0.67           0.87 (0.47--1.6)    0.67             50

  TBD        1 (0.8)        5 (2.8)            0.24           0.26 (0.3--2.279    0.22             6

  GRD        25 (18.9)      25 (14.1)          0.25           1.4 (0.77--2.6)     0.25             50

  Sec14-PH   12 (9.1)       11 (6.2)           0.34           1.5 (0.64--3.53)    0.34             23

  HLR        25 (18.9)      29 (16.4)          0.55           1.19 (0.66--2.15)   0.56             54

  CTD        13 (9.8)       16 (9)             0.80           1.09 (0.5--2.37)    0.80             29

  NLS        0              1 (0.6)            1              1 (0.99--1.01)      1                1

  SBR        0              2 (1.1)            0.5            1.01 (0.99--1.02)   0.99             2

  Others     43 (32.6)      68 (38.4)          0.29           0.77 (0.48--1.24)   0.77             111
  ---------------------------------------------------------------------------------------------------------

Differences in the frequency of mutations in the different domains of the *NF1* gene between the OPG and the non-OPG group. \* Chi-squared test; \*\* logistic regression.
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###### 

Distribution of *NF1* mutation types in the OPG and non-OPG group.

  -------------------------------------------------------------------------------------------------------------------------------
  Mutation Type     OPG *n* (%)\   Non-OPG *n* (%)\   *p*-Value \*   *p*-Value^§^   OR (95% CI)         *p*-Value \*\*   Total\
                    *n*= 132       *n* = 177                                                                             Number
  ----------------- -------------- ------------------ -------------- -------------- ------------------- ---------------- --------
  Large deletions   5 (3.8)        3 (1.7)            0.29                          2.28 (0.53--9.7)    0.26             8

  Frameshift        41 (31.1)      60 (33.9)          0.59                          0.87 (0.54--1.42)   0.59             101

  Inframe           3 (2.3)        3 (1.7)            0.70                          1.34 (0.26--6.7)    0.71             6

  Missense          9 (6.8)        24 (13.6)          0.06                          0.46 (0.20--10.4)   0.062            33

  Nonsense          45 (34.1)      40 (22.6)          0.025          0.15           1.77 (1.07--2.93)   0.26             85

  Splicing          29 (22)        47 (26.6)          0.35                          0.77 (0.45--1.32)   0.35             76
  -------------------------------------------------------------------------------------------------------------------------------

Differences in the frequency of the different types of the *NF1* gene mutations between the OPG and non-OPG group. \* Chi-squared test; \*\* logistic regression; ^§^ after Bonferroni's correction.

[^1]: These authors share equal contribution.
